As a global pharmaceutical company with a biotech mindset and a proven ability to provide new, life-changing therapies, Ipsen is a leading player in its core therapeutic areas.

Contact us


Craig Marks Adrien Dupin de Saint-Cyr
Vice President, Investor Relations Investor Relations Manager
+44 7584 349 193 +33 6 64 26 17 49

Contact us

YTD 2021 sales update - Webcast details

Date: Thursday 21 October 2021

Time: Conference call and webcast – 2:30pm CEST / 8:30am EST

Standard International: +44 (0) 2071 928 000

France and continental Europe: +33 (0) 1 76 70 07 94

U.K.: 08445 718 892

U.S.: (631) 510-7495

Conference ID: 4312698

Ipsen in Brief

Ipsen in Brief 2021

Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.


Registration document

2020 Universal Registration Document

This registration document contains forward-looking statements about Ipsen’s targets and forecasts, including the Annual Financial Report. The registration document provides a comprehensive information about the Company its activities, financial information, colleagues and legal information


Capital Markets Day

Capital Markets Day

Research & Development pipeline

Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules.

Learn more

We are focused on accelerating our sales growth while improving our profitability and cash flow generation, in order to further invest in business development to build an innovative and sustainable pipeline and to maintain the growth momentum of the business.

Aymeric Le Chatelier, CFO
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021